Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at twitter.com/novartis.
POSTED
01-25-18
Novartis Releases 2017 Corporate Responsibility Report
For the fifth consecutive year, Novartis is publishing an annual Corporate Responsibility (CR) Report. The report is divided into four chapters based on our CR material clusters: access to healthcare, innovation, patient health and safety and ethical business practices. Each chapter provides re...
POSTED
01-25-17
Novartis Releases 2016 Corporate Responsibility Performance Report
Novartis has published its Corporate Responsibility (CR) Performance Report for 2016. This year’s report provides even more context on the company’s CR performance, as well as views and comments on trends and challenges within the healthcare industry.
This is the fourth consecutive year N...
POSTED
01-27-16
Novartis Releases 2015 Corporate Responsibility Performance Report
Novartis has published its 2015 Corporate Responsibility (CR) Performance Report. The report is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level, making it the first comprehensive level-report in the healthc...
POSTED
10-30-15
Novartis Foundation and Partners Launch New Hypertension Program in Ghana
The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management and control in Ghana.
With the innovative...
POSTED
09-07-15
Novartis Foundation Presents Healthcare Models and Disease Elimination Programs at ECTMIH
The Novartis Foundation and its partners will highlight progress towards transforming the health of the poorest populations at the 9th European Congress on Tropical Medicine and International Health (ECTMIH) held in Basel from September 6 – 10. Updates on nine Novartis...
POSTED
07-24-15
Sandoz Launches Breathe Africa Program to Improve Asthma Diagnosis, Treatment and Patient Outcomes in Zambia
Sandoz today announced the launch of Breathe Africa, a respiratory health program aimed at improving the diagnosis and treatment of asthma through sharing medical expertise and donating medicines. The program will start in Zambia and will bring European doctors to work...
POSTED
04-24-15
Novartis Pharmaceuticals Corporation is First Company to Receive Number One Ranking Two Years in a Row on DiversityInc Top 50 Companies for Diversity List
Novartis Pharmaceuticals Corporation (NPC) has been named the top company for diversity for the second year in a row on the annual DiversityInc Top 50 Companies for Diversity listing. DiversityInc announced the results of its 2015 Top 50 Companies for Diversity on April 23 at an awards...
POSTED
03-03-15
Sandoz Announces Training Program for Midwives in Ethiopia, to Reduce Maternal and Newborn Mortality
Sandoz today announced the launch of a new program, New Life & New Hope, to improve maternal and child health and reduce mortality associated with childbirth. The program, ahead of International Women’s Day on March 8, kicks-off with the completion of the first in a series of Sando...
POSTED
07-09-14
Novartis Releases 2013 Corporate Responsibility Performance Report Using Best-in-class Reporting Standard, Increasing Transparency
Novartis has published a Corporate Responsibility (CR) Performance Report for 2013. The report reflects the best-in-class reporting standard, the Global Reporting Initiative’s (GRI) G4 guidelines, one year in advance of required implementation.
“Our corporate responsibility wo...
POSTED
06-30-14
Sandoz Joins Forces With United Nations to Combat a Leading Cause of Child Mortality Worldwide
- Sandoz makes long-term commitment to support UN initiative on child mortality
- Commitment to UN Every Newborn Action Plan involves development and supply of recommended WHO formulation for treating childhood pneumonia
- Pneumonia is the leading cause of d...
